期刊文献+

择期冠脉介入患者对比剂肾病影响因素分析 被引量:4

Risk factors of contrast-induced nephropathy in patients undergoing selective percutaneous coronary intervention
下载PDF
导出
摘要 目的分析常规水化治疗情况下择期经皮冠状动脉介入术(PCI)患者发生对比剂肾病(CIN)的影响因素。方法连续入选我院2010年2月~2011年10月择期行PCI的冠心病患者216例,于冠脉介入围手术期给予0.9%氯化钠以1.5 mL/(kg.h)静点水化治疗,记录患者术前24 h、术后72 h内血肌酐值,分析CIN发生情况及相关影响因素。结果择期冠脉介入患者CIN发生率为8.33%(18/216),与非CIN患者比较,CIN患者年龄升高、更多合并糖尿病、肾功能下降、术中对比剂用量增多(P<0.05或P<0.01)。Logistic回归分析显示,年龄≥70岁、糖尿病、术前eGFR<60 mL/(min.1.73m2)、对比剂用量>150 mL是CIN的独立危险因素(P均<0.01)。结论常规水化治疗下冠脉介入患者仍有8.33%发生CIN,其中年龄、合并糖尿病、术前肾功能下降及对比剂用量是CIN独立危险因素,对于高危患者应高度警惕并积极预防CIN的发生。 Objective To study the risk factors of contrast-media induced nephropathy(CIN) in patients undergoing selective percutaneous coronary intervention(PCI) with routine hydration.Methods A total of 216 patients undergoing selective PCI from February 2010 to October 2011 were enrolled in this study,all patients were received infusion of saline [1.5 mL/(kg·h)] in preoperative period of PCI.Levels of serum creatinine were determined 24 hours before and 72 hours after PCI.Results Among the 216 patients,18 patients developed CIN(8.33%).The age,diabetic mellitus,decreased renal function,and contrast medium dosage in CIN patients were significantly different from those in non-CIN patients(P〈0.05 or P〈0.01).Identified by regression,age≥70,diabetes mellitus,preoperative eGFR60 mL/(min·1.73 m^2) and volume of contrast medium were independent risk factors of CIN.Conclusions With routine hydration,incidence of CIN was 8.33% among patients undergoing selective PCI.Age,accompanied with diabetic mellitus,decreased renal function and contrast medium dosage are the independent risk factors,which should be highly alerted in high risk patients.
出处 《山东医药》 CAS 2012年第4期22-24,共3页 Shandong Medical Journal
关键词 经皮冠状动脉介入术 对比剂肾病 危险因素 percutaneous coronary intervention contrast-media induced nephropathy risk factors
  • 相关文献

参考文献11

  • 1杜敏,马淑梅.造影剂肾病[J].实用药物与临床,2009,12(1):55-58. 被引量:28
  • 2Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention [ J]. Circulation, 2002,105 (19) :2259-2264.
  • 3Aimini M, Salarifar M, amirbaigloo A, et al. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial [ J]. Trials, 2009,10:45-48.
  • 4李海德,李贵双,张文泉,张玉红.冠状动脉介入诊疗术患者造影剂肾病的危险因素研究[J].山东大学学报(医学版),2009,47(10):98-101. 被引量:6
  • 5Topark O. Risk Markers for contrast-induced nephropathy [ J ]. Am J Med Sci, 2007,334(4) :283-290.
  • 6张翩,倪兆慧,王玲,何奔,王肖龙,邱建平,郑昌柱,杨光敏,朱爱国.冠状动脉介入术患者造影剂肾病的危险因素多中心调查[J].中国中西医结合肾病杂志,2010,11(3):214-218. 被引量:24
  • 7Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy [J]. Circulation, 2006,113(14) :1799-1806.
  • 8Asif A, Preston RA, Roth D. [J]. Am J Ther, 2003,10(2) : Radiocontrast -induced nephropathy 137-147.
  • 9Nation Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification [J]. Am J Kidney Dis, 2002,39(2 suppl 1) :SI-266.
  • 10Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables [ J ]. Am J Cardiol, 2005,95( 1 ) :13-19.

二级参考文献25

共引文献54

同被引文献44

  • 1侯湘岭,刘慧,王伟红,陈伟,付晨阳.不同水化方法对冠状动脉介入术后造影剂肾病的临床观察[J].中华临床医师杂志(电子版),2011,5(13):3968-3970. 被引量:18
  • 2霍勇,洪涛.经皮冠状动脉介入技术是当前治疗急性冠状动脉综合征的重要手段[J].中华心血管病杂志,2006,34(6):481-482. 被引量:10
  • 3Anderson JL,Adams CD,Antman EM,etal. ACA2/AHA 2007 guide- lines for the management of patients with unstable angina/non-ST-el- evation myocardial infarction..A report oF the American college o: car- diology/American heart association task force on practice guidelines [J]. J Am Coll Cardiol,2007,50(1) ..e155-e157.
  • 4Persson PB, Hansell P,Liss P. Pathophysiology o{ contrast medium- induced nephropathy[J]. Kidney Int, 2005,68 (1) .. 14-22.
  • 5Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: Effectiveness of drugs for preventing contrast-induced nephropathy [J]. Ann Intern Med,2008,148(4) : 284-294.
  • 6Giuseppe P, Annunziata N, Massimo C, et al. Usefulness of statin pre- treatment to prevent contrast-induced nephropathy and to improvelong-term outcome in patients undergoing percutaneous coronary in- tervention [J]. Am J Cardiology,2008,101(3) : 279-285.
  • 7Attallah N,Yassine L,Musial J,et al. The potential role of statins in contras nephropathy[J]. Clin Nephrol, 2004,62(4) : 273-278.
  • 8Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term out- come in patients undergoing percutaneous coronary intervention [J]. Am J Cardiol,2008,101(3) :279-285.
  • 9陈光铃,苏津自.阿托伐他汀改善对比剂对肾功能的短期影响[J].中华心血管病杂志,2009,37(5):389-393. 被引量:35
  • 10韩雅玲,姚天明.心血管内科专业新进展及展望[J].解放军医学杂志,2010,35(4):355-359. 被引量:49

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部